KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Operating Leases (2020 - 2025)

Vir Biotechnology (VIR) has disclosed Operating Leases for 6 consecutive years, with $89.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 9.03% to $89.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.1 million through Dec 2025, down 9.03% year-over-year, with the annual reading at $89.1 million for FY2025, 9.03% down from the prior year.
  • Operating Leases hit $89.1 million in Q4 2025 for Vir Biotechnology, down from $91.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $133.6 million in Q4 2021 to a low of $66.6 million in Q1 2021.
  • Historically, Operating Leases has averaged $103.9 million across 5 years, with a median of $103.5 million in 2024.
  • Biggest five-year swings in Operating Leases: soared 467.35% in 2021 and later dropped 19.35% in 2024.
  • Year by year, Operating Leases stood at $133.6 million in 2021, then decreased by 4.18% to $128.0 million in 2022, then decreased by 12.74% to $111.7 million in 2023, then fell by 12.34% to $97.9 million in 2024, then fell by 9.03% to $89.1 million in 2025.
  • Business Quant data shows Operating Leases for VIR at $89.1 million in Q4 2025, $91.2 million in Q3 2025, and $93.4 million in Q2 2025.